JP2021502083A5 - - Google Patents

Download PDF

Info

Publication number
JP2021502083A5
JP2021502083A5 JP2020524809A JP2020524809A JP2021502083A5 JP 2021502083 A5 JP2021502083 A5 JP 2021502083A5 JP 2020524809 A JP2020524809 A JP 2020524809A JP 2020524809 A JP2020524809 A JP 2020524809A JP 2021502083 A5 JP2021502083 A5 JP 2021502083A5
Authority
JP
Japan
Prior art keywords
cancer
encoded
seq
related protein
peptides listed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2020524809A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021502083A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/059849 external-priority patent/WO2019094607A2/en
Publication of JP2021502083A publication Critical patent/JP2021502083A/ja
Publication of JP2021502083A5 publication Critical patent/JP2021502083A5/ja
Ceased legal-status Critical Current

Links

JP2020524809A 2017-11-08 2018-11-08 がん関連タンパク質由来の免疫原性ヘテロクリティックペプチドおよびその使用の方法 Ceased JP2021502083A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762583292P 2017-11-08 2017-11-08
US62/583,292 2017-11-08
US201762592884P 2017-11-30 2017-11-30
US62/592,884 2017-11-30
PCT/US2018/059849 WO2019094607A2 (en) 2017-11-08 2018-11-08 Immunogenic heteroclitic peptides from cancer-associated proteins and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2021502083A JP2021502083A (ja) 2021-01-28
JP2021502083A5 true JP2021502083A5 (enExample) 2021-12-09

Family

ID=66437981

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020524809A Ceased JP2021502083A (ja) 2017-11-08 2018-11-08 がん関連タンパク質由来の免疫原性ヘテロクリティックペプチドおよびその使用の方法

Country Status (11)

Country Link
US (1) US20210177955A1 (enExample)
EP (1) EP3707152A4 (enExample)
JP (1) JP2021502083A (enExample)
KR (1) KR20200070405A (enExample)
CN (1) CN111655714A (enExample)
AU (1) AU2018366131A1 (enExample)
CA (1) CA3081710A1 (enExample)
IL (1) IL274434A (enExample)
MX (1) MX2020004829A (enExample)
SG (1) SG11202004107YA (enExample)
WO (1) WO2019094607A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
CN110506107A (zh) 2016-11-30 2019-11-26 阿德瓦希斯公司 靶向复发性癌症突变的免疫原性组合物及其使用方法
US11179339B2 (en) 2017-09-19 2021-11-23 Advaxis, Inc. Compositions and methods for lyophilization of bacteria or listeria strains
MA53543A (fr) 2018-09-04 2021-07-14 Treos Bio Ltd Vaccins peptidiques
WO2021230247A1 (ja) * 2020-05-12 2021-11-18 大日本住友製薬株式会社 癌を処置するための医薬組成物
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
WO2024086846A1 (en) * 2022-10-21 2024-04-25 University Of Florida Research Foundation, Incorporated Methods and compositions for immunizing against campylobactor hepaticus
CN117552115B (zh) * 2024-01-12 2024-03-26 天津鲸鹏生物科技有限责任公司 用于诱导肿瘤特异性免疫响应的通用型抗原肽库及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9340577B2 (en) * 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
JP4776131B2 (ja) * 1999-11-18 2011-09-21 エピミューン インコーポレイテッド ヘテロクリティックアナログおよび関連方法
CA2400215A1 (en) * 2000-02-23 2001-08-30 Epimmune Inc. Hla binding peptides and their uses
US8771702B2 (en) * 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
DE60336227D1 (de) * 2002-06-06 2011-04-14 Oncotherapy Science Inc Gene und proteine mit bezug zu menschlichem kolonkrebs
GB0700284D0 (en) * 2007-01-08 2007-02-14 Glaxosmithkline Biolog Sa Combination therapy
DK2114993T3 (da) * 2007-01-15 2012-10-22 Glaxosmithkline Biolog Sa Vaccine
US8166971B2 (en) * 2007-03-15 2012-05-01 Ric Investments, Llc End-tidal gas estimation system and method
US9017660B2 (en) * 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US9650639B2 (en) * 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
WO2010018136A1 (en) * 2008-08-12 2010-02-18 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Minigene comprising htpa signal peptide, t-cell epitopes, e. coli ltb and furin sensitive linkers
US9109007B2 (en) * 2010-08-18 2015-08-18 Purdue Pharma L.P. MHC-I restricted epitopes containing non-natural amino acid residues
WO2012125551A1 (en) * 2011-03-11 2012-09-20 Advaxis Listeria-based adjuvants
HK1204261A1 (en) * 2012-01-13 2015-11-13 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
JP2017522322A (ja) * 2014-07-18 2017-08-10 アドバクシス， インコーポレイテッド 抗腫瘍応答を引き出すためのリステリアベースの免疫原性組成物
SG11201700092XA (en) * 2014-07-18 2017-02-27 Advaxis Inc Recombinant listeria strain expressing heterologous antigen fusion proteins and methods of use thereof
MA41644A (fr) * 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
TW201723171A (zh) * 2015-09-15 2017-07-01 艾法西斯公司 基於李斯特菌屬之免疫原性組成物及其於癌症預防與治療中之使用方法
EP4130026A1 (en) * 2015-11-20 2023-02-08 Memorial Sloan-Kettering Cancer Center Methods and compositions for treating cancer
EP3481854A4 (en) * 2016-07-05 2020-07-29 Advaxis, Inc. LISTERIA-BASED IMMUNOGENIC COMPOSITIONS INCLUDING WILMS TUMOR PROTEIN ANTIGENS AND CORRESPONDING METHODS OF USE
CN110506107A (zh) * 2016-11-30 2019-11-26 阿德瓦希斯公司 靶向复发性癌症突变的免疫原性组合物及其使用方法

Similar Documents

Publication Publication Date Title
JP2021502083A5 (enExample)
US20190032064A1 (en) Personalized Delivery Vector-Based Immunotherapy and Uses Thereof
AU2003259109A1 (en) Mesothelin vaccines and model systems
IL261266B2 (en) Peptides, combination of peptides and drug-based cells for use in immunotherapy against bladder cancer and other types of cancer
US20160220652A1 (en) Methods of using recombinant listeria vaccine strains in disease immunotherapy
JP2017195888A5 (enExample)
CA3016410A1 (en) Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers
JP5477991B2 (ja) 悪性新生物治療剤に利用可能な抗原性ポリペプチド
JP2018508212A5 (enExample)
CN106459887A (zh) 重组李斯特菌疫苗菌株及其制备方法
WO2016191545A4 (en) Personalized delivery vector-based immunotherapy and uses thereof
JP2019528693A5 (enExample)
CA2992506A1 (en) Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
JP2013526837A (ja) 組換えリステリア株およびそれを含む医薬組成物
US9296784B2 (en) Mesothelin vaccines and model systems
CN107250366A (zh) 重组李斯特菌疫苗菌株及其用于癌症免疫疗法的方法
AU748250B2 (en) Tumor antigen peptide derivatives
JP2017507943A5 (enExample)
CA3108578A1 (en) B*44 restricted peptides for use in immunotherapy against cancers and related methods
US11285197B2 (en) Mesothelin vaccines and model systems
KR20180043381A (ko) 재조합 리스테리아 백신 균주 및 암 면역요법에서 이를 이용하는 방법
CA3097698A1 (en) A*03 restricted peptides for use in immunotherapy against cancers and related methods
JP2018512165A (ja) 癌の治療のための免疫原性融合タンパク質
US20210107941A1 (en) Novel cell epitopes and combination of cell epitopes for use in the immunotherapy of myeloma and other cancers
JPWO2019226939A5 (enExample)